Topic: Genentech

12Jun/18

FDA Approves Genentech’s Rituxan For Pemphigus Vulgaris

The U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterized by progressive painfulRead More…

14May/18

FDA Grants Priority Review of Genentech’s Tecentriq

Genentech, a member of the Roche Group today announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab), paclitaxelRead More…